FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * FRY JOHN A 2. Issuer Name and Ticker or Trading Symbol vTv Therapeutics Inc. [ VTVT ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)
C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, SUITE 310
3. Date of Earliest Transaction (MM/DD/YYYY)
7/1/2022
(Street)
HIGH POINT, NC 27265
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Director stock option (right to buy)  $0.72  7/1/2022    A     137077       (1) 7/1/2032  Class A Common Stock  137077  $0  137077  D   
Director stock option (right to buy)  $5.35                   (3) 5/12/2026  Class A Common Stock  17500    17500 (2) D   
Director stock option (right to buy)  $5.31                   (4) 5/1/2027  Class A Common Stock  15000    15000 (2) D   
Director stock option (right to buy)  $1.79                   (5) 4/30/2028  Class A Common Stock  15000    15000 (2) D   
Director stock option (right to buy)  $1.45                   (6) 4/29/2029  Class A Common Stock  15000    15000 (2) D   
Director stock option (right to buy)  $2.65                   (7) 6/11/2030  Class A Common Stock  15000    15000 (2) D   
Director stock option (right to buy)  $2.54                   (8) 5/3/2031  Class A Common Stock  15000    15000 (2) D   

Explanation of Responses:
(1)  An option to purchase 80,128 shares vested immediately on July 1, 2022. The remaining option to purchase 56,949 shares vests on June 1, 2023.
(2)  On May 16, 2016, May 3, 2017, May 2, 2018, May 1, 2019, June 15, 2020 and May 5, 2021, the reporting person filed Form 4s which inadvertently aggregated options to purchase shares of Class A common stock with different exercise prices and expiration dates. These errors have been corrected in the options beneficially owned in this Form 4.
(3)  An option to purchase 138 shares vested immediately on May 12, 2016. The remaining option to purchase 17,362 shares vests in equal monthly installments over the three-year period beginning on May 12, 2016.
(4)  Vests in equal monthly installments over the three-year period beginning on May 1, 2017.
(5)  Vests in equal monthly installments over the three-year period beginning on April 30, 2018.
(6)  Vests in equal monthly installments over the three-year period beginning April 29, 2019.
(7)  Vests in equal monthly installments over the three-year period beginning June 11, 2020.
(8)  Vests in equal monthly installments over the three-year period beginning May 3, 2021.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
FRY JOHN A
C/O VTV THERAPEUTICS INC.
3980 PREMIER DRIVE, SUITE 310
HIGH POINT, NC 27265
X



Signatures
/s/ Richard S. Nelson as Attorney-in-Fact 7/6/2022
**Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more vTv Therapeutics Charts.
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more vTv Therapeutics Charts.